NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.

Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock HTG774 25 March 2026 25 March 2026 Percutaneous insertion of a catheter-based left ventricular ...

Evidence-based recommendations for the health and social care sector, developed by independent committees, including professionals and lay members, and consulted on by stakeholders.

Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on ...

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441] ...

People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further ...

Public Health Minister Sharon Hodgson said: "Every woman with endometriosis deserves fertility care that recognises the complexity of her condition. This landmark guidance will ensure women can access ...

Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults ...

Sophie Cooper, Senior Scientific Adviser, explains the importance of the recently published EQ-5D-5L value set and how it has ...

This guidance updates and replaces NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088). Next review: This guidance will be ...

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839] Medicines evaluation Not selected 10 March 2026 Peginterferon ...

Fezolinetant (also called Veoza and made by Astellas Pharma) is recommended to treat moderate to severe symptoms in final draft NICE guidance. Hot flushes and night sweats can hugely affect daily life ...